CN101745080A - Chinese patent medicine for treating leukemia - Google Patents
Chinese patent medicine for treating leukemia Download PDFInfo
- Publication number
- CN101745080A CN101745080A CN201010102791A CN201010102791A CN101745080A CN 101745080 A CN101745080 A CN 101745080A CN 201010102791 A CN201010102791 A CN 201010102791A CN 201010102791 A CN201010102791 A CN 201010102791A CN 101745080 A CN101745080 A CN 101745080A
- Authority
- CN
- China
- Prior art keywords
- radix
- prescription
- chinese patent
- patent medicine
- cervi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a Chinese patent medicine for treating leukemia, comprising a first prescription and a second prescription, wherein the first prescription comprises scutellaria, coptis, bupleurum, curcuma aromatica, yam, atractylodes macrocephala, white peony root, codonopsis, astragalus, angelica, raw rehmannia, tangerine peel and licorice, and the second prescription is composed of deer gall and deer marrow. The Chinese patent medicine has the advantages of easy taking, no toxic or side effect, low cost and significant treating effect, and can treat leukemia once and for all.
Description
Technical field
The present invention relates to field of medicaments, the leukemic Chinese patent medicine of particularly a kind of treatment.
Background technology
Leukemia is a kind of difficult and complicated illness, and kind has a lot.Present Therapeutic Method mainly contains methods such as chemotherapy, bone marrow transplantation and hematopoietic stem cell transplantation.Chemotherapy is painful big, and side effect is big, and unsatisfactory curative effect can't effect a radical cure leukemia; Bone marrow transplantation and hematopoietic stem cell transplantation are very little because of joining the type possibility of success, and donor is difficult to find.The medical expense of above-mentioned Therapeutic Method is high, causes heavy financial burden to the patient.
Summary of the invention
The present invention is intended to overcome the defective of above-mentioned existing treatment leukemia method, provides a kind of treatment leukemic Chinese patent medicine.
The inventor has carried out deep analysis to the reason that leukemia forms, and leukemia pathogenic factor complexity all can cause leukemia as X ray, ionizing radiation, chemical factor and inherited genetic factors or the like.Leukemia is the malignant clone disease of a class hematopoietic stem cell.Out of control, the dysdifferentiation of Leukemia Cell Proliferation among its clone.Apoptosis is obstructed and is stuck in cytocerastic different phase.The a large amount of hypertrophy of leukaemia in bone marrow and other hemopoietic tissue, liver, spleen, lymphocyte and each internal organs are soaked in accumulation, have suppressed the normal hematopoiesis function.Clinical manifestation is a splenomegaly.Leukemic natural history is divided into acute and chronic two big classes.The cell differentiation of acute leukemia is stuck in the stage early, mostly is the early stage juvenile cell of germinal cell, and PD is rapid, and natural history only needs some months.The cell differentiation of chronic leukemia is stuck in late phase, mostly is ripe juvenile cell, and PD is slow, and natural history is several years or several years.The traditional Chinese medical science thinks that leukemia treating should soothing the liver, spleen invigorating.Liver controlling conveyance and dispersion, The spleen has the function to transport and transform nutrients.Spleen can be dredged blood, takes the photograph blood, hemopoietic, cross hemofiltration, purify the blood.
The inventor sums up for many years clinical experience and thinks: the most splenomegalies of leukemia people, the degree of splenomegaly is also different, and most patients cytopenia can occur also with the cell thrombocytopenia during severe splenomegaly, and erythrocyte, leukocyte, platelet can single minimizings or reduced simultaneously.
The present invention is a kind of to treat leukemic Chinese patent medicine, comprises first prescription and second prescription.
First prescription is made by the pharmacodynamic raw materials of following proportioning:
Radix Scutellariae 10-15g, Rhizoma Coptidis 3-6g, Radix Bupleuri 10-15g, Radix Curcumae 12-15g, Rhizoma Dioscoreae 10-15g,
Rhizoma Atractylodis Macrocephalae 10-12g, Radix Paeoniae Alba 10-15g, Radix Codonopsis 15-20g, Radix Astragali 15-20g, Radix Angelicae Sinensis 10-15g,
Radix Rehmanniae 10-15g, Pericarpium Citri Reticulatae 8-12g, Radix Glycyrrhizae 6-10g.
Radix Scutellariae, Rhizoma Coptidis, Radix Bupleuri, Radix Curcumae have the soothing liver-QI effect, and Rhizoma Dioscoreae, the Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba have the effect of spleen invigorating, but Radix Codonopsis, Radix Astragali QI invigorating, but Radix Angelicae Sinensis, Radix Rehmanniae hemopoietic, nourish blood, enrich blood, the Pericarpium Citri Reticulatae promoting the circulation of blood, Radix Glycyrrhizae is as holding up medicine.
Second prescription is made by following pharmacodynamic raw materials:
One of Fel Cervi, Os Cervi marrow one tool.
Above-mentioned Fel Cervi, Os Cervi marrow concentration extraction are brewed into unguentum.
Fel Cervi contains bilirubin and has refrigeration function, lipotropism matter, and the anti-peroxidation physiological reaction, the protection human body cell is not destroyed by free radical, improves the human body immunity.Bone marrow contains haemachrome, and tonifying YIN is supported marrow, and the effect of short people's cell activation is arranged.
Using method: first prescription and second prescription use simultaneously, and first prescription is decocted in water for oral dose, the second prescription mixing in water for oral taking, every day three times, each 5g.The course of treatment: one course of treatment of January, take effect general 1-3 course of treatment.A blood routine examination was done in treatment every 10 days.
Be suitable for the scope of we's treatment: 1, the course of disease must not be above three months; 2, leukocyte is higher or lower than normal value, patient's effective percentage that platelet is lower than normal value reaches 100%, and cure rate reaches 98%; 3, patient temperature is between 36.6 degrees centigrade to 37 degrees centigrade, and cure rate can reach 98%; 4, male patient does chemotherapy and is no more than 3 times, and women patient does chemotherapy and is no more than 2 times, all can reply normal.
Advantage of the present invention is a taking convenience, has no side effect, and is cheap, evident in efficacy, can effect a radical cure leukemia.
The specific embodiment
1 one kinds of leukemic Chinese patent medicines of treatment of embodiment comprise first prescription and second prescription.
First prescription is made by the pharmacodynamic raw materials of following proportioning:
Radix Scutellariae 10g, Rhizoma Coptidis 3g, Radix Bupleuri 10g, Radix Curcumae 12g, Rhizoma Dioscoreae 10g, Rhizoma Atractylodis Macrocephalae 10g, Radix Paeoniae Alba 10g,
Radix Codonopsis 15g, Radix Astragali 15g, Radix Angelicae Sinensis 10g, Radix Rehmanniae 10g, Pericarpium Citri Reticulatae 8g, Radix Glycyrrhizae 6g.
Second prescription is made by following pharmacodynamic raw materials:
One of Fel Cervi, Os Cervi marrow one tool.
Above-mentioned Fel Cervi, Os Cervi marrow concentration extraction are brewed into unguentum.
2 one kinds of leukemic Chinese patent medicines of treatment of embodiment comprise first prescription and second prescription.
First prescription is made by the pharmacodynamic raw materials of following proportioning:
Radix Scutellariae 15g, Rhizoma Coptidis 6g, Radix Bupleuri 15g, Radix Curcumae 15g, Rhizoma Dioscoreae 15g, Rhizoma Atractylodis Macrocephalae 12g, Radix Paeoniae Alba 15g,
Radix Codonopsis 20g, Radix Astragali 20g, Radix Angelicae Sinensis 15g, Radix Rehmanniae 15g, Pericarpium Citri Reticulatae 12g, Radix Glycyrrhizae 10g.
Second prescription is made by following pharmacodynamic raw materials:
One of Fel Cervi, Os Cervi marrow one tool.
Above-mentioned Fel Cervi, Os Cervi marrow concentration extraction are brewed into unguentum.
Using method: first prescription and second prescription use simultaneously, and first prescription is decocted in water for oral dose, the second prescription mixing in water for oral taking, every day three times, each 5g.The course of treatment: one course of treatment of January, take effect general 1-3 course of treatment.A blood routine examination was done in treatment every 10 days.
Clinical case
The Wang, the man, 19 years old, people from Laizhou City, Shandong Province, the course of disease 3 months, on April 17th, 2006 went to a doctor.Erythrocyte 1.9, leukocyte 2.7, platelet 38 was taken the treatment of this medicine after 30 days, and erythrocyte reaches 4.7, leukocyte 5.3, platelet 105.
Show that according to inventor's 500 many cases patient data for the treatment of effective percentage reaches 100%, cure rate reaches 98%, through can curing 2 to 3 courses of treatment, and can not recur.
Claims (1)
1. the leukemic Chinese patent medicine of treatment comprises first prescription and second prescription, it is characterized in that first prescription made by the pharmacodynamic raw materials of following proportioning:
Radix Scutellariae 10-15g, Rhizoma Coptidis 3-6g, Radix Bupleuri 10-15g, Radix Curcumae 12-15g, Rhizoma Dioscoreae 10-15g,
Rhizoma Atractylodis Macrocephalae 10-12g, Radix Paeoniae Alba 10-15g, Radix Codonopsis 15-20g, Radix Astragali 15-20g, Radix Angelicae Sinensis 10-15g,
Radix Rehmanniae 10-15g, Pericarpium Citri Reticulatae 8-12g, Radix Glycyrrhizae 6-10g;
Second prescription is made by following pharmacodynamic raw materials:
One of Fel Cervi, Os Cervi marrow one tool.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010102791A CN101745080A (en) | 2010-01-29 | 2010-01-29 | Chinese patent medicine for treating leukemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010102791A CN101745080A (en) | 2010-01-29 | 2010-01-29 | Chinese patent medicine for treating leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101745080A true CN101745080A (en) | 2010-06-23 |
Family
ID=42473095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010102791A Pending CN101745080A (en) | 2010-01-29 | 2010-01-29 | Chinese patent medicine for treating leukemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101745080A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726776A (en) * | 2016-03-03 | 2016-07-06 | 郑州大学 | Traditional Chinese medicine for alleviating bone marrow inhibition reaction caused by paclitaxel chemotherapy |
| CN108295236A (en) * | 2018-04-20 | 2018-07-20 | 董佩鸽 | A kind of Chinese medicine preparation for treating blood disease |
| CN112515177A (en) * | 2020-12-24 | 2021-03-19 | 吉林省东鳌鹿业科技开发有限公司 | Deer bone marrow small molecule peptide freeze-dried powder composition and preparation method thereof |
-
2010
- 2010-01-29 CN CN201010102791A patent/CN101745080A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726776A (en) * | 2016-03-03 | 2016-07-06 | 郑州大学 | Traditional Chinese medicine for alleviating bone marrow inhibition reaction caused by paclitaxel chemotherapy |
| CN108295236A (en) * | 2018-04-20 | 2018-07-20 | 董佩鸽 | A kind of Chinese medicine preparation for treating blood disease |
| CN112515177A (en) * | 2020-12-24 | 2021-03-19 | 吉林省东鳌鹿业科技开发有限公司 | Deer bone marrow small molecule peptide freeze-dried powder composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100356972C (en) | Chinese medicine for treating amblyopia and myopia | |
| CN100496586C (en) | Medicinal liquor for treating hyperosteogency and koilorrhachic | |
| CN103316174B (en) | Traditional Chinese medicinal composition for treating acute cholecystitis and preparation method thereof | |
| CN102058805B (en) | Oral medicine for preventing and treating leukocytopenia caused by chemotherapy | |
| CN100421717C (en) | A Chinese medicine for treating leukemia | |
| CN102614442A (en) | Traditional Chinese drug capsules with effects of immunity enhancing, blood reinforcing and antiemesis | |
| CN104258203A (en) | Traditional Chinese medicine combination for preventing and curing leucopenia caused by radiotherapy | |
| CN104189774A (en) | Traditional Chinese medicine for treating chronic hepatitis B | |
| CN103784602A (en) | Traditional Chinese medicine for treating iron-deficiency anemia | |
| CN101745080A (en) | Chinese patent medicine for treating leukemia | |
| CN103446554A (en) | Traditional Chinese medicine composition for treating scapulohumeral periarthritis | |
| CN101664486A (en) | Chinese medicinal preparation for treating tumors | |
| CN105362904A (en) | Qi tonifying and blood nourishing traditional Chinese medicinal pill and preparation method thereof | |
| CN103341037B (en) | Traditional Chinese medicine composition for treating azoospermia | |
| CN101129893A (en) | Traditional Chinese medicine for treating cervical vertebra disease combined with diarrhea | |
| CN1686227A (en) | Menstruation regulating powder | |
| CN101695531A (en) | Chinese medicinal decoction for treating children alopecia | |
| CN105434864A (en) | Traditional Chinese medicine composition for treating malignant tumor | |
| CN101732622A (en) | Chinese medicament for treating ischidrosis | |
| CN112206274A (en) | Traditional Chinese medicine prescription for treating semen abnormality | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN1192916A (en) | Chinese medicine for treatment of gout | |
| CN103893629A (en) | Chinese medicinal composition for treating child anorexia | |
| CN1562262A (en) | Chinese herbal medicine for curing hyperthyroidism | |
| CN100376265C (en) | Medicine for treating sterility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20100623 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |